Crossmark

Long-acting B-2 agonists (LABA) or long-acting muscarinic antagonists (LAMA): which one may be the first option in group A COPD patients?

Crossref DOI link: https://doi.org/10.1007/s00228-024-03637-1

Published Online: 2024-02-23

Published Print: 2024-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Turan, Onur https://orcid.org/0000-0001-6320-0470
Ogan, Nalan https://orcid.org/0000-0001-5232-3803
Bozkus, Fulsen https://orcid.org/0000-0002-6498-4390
Sarıoğlu, Nurhan https://orcid.org/0000-0002-5180-9649
Turan, Pakize Ayşe https://orcid.org/0000-0002-9325-4303
Satıcı, Celal https://orcid.org/0000-0002-5457-9551
License Information

Text and Data Mining valid from 2024-02-23

Version of Record valid from 2024-02-23
More Information

Article History

Received: 9 October 2023

Accepted: 23 January 2024

First Online: 23 February 2024

Declarations

:

: All authors have approval about this manuscript.

: The authors declare no competing interests.